Nick Leschly Net Worth

The estimated Net Worth of Nick Leschly is at least $60.2 Миллион dollars as of 11 January 2023. Mr. Leschly owns over 4,290 units of Bluebird bio Inc stock worth over $162,486 and over the last 11 years he sold BLUE stock worth over $46,878,412. In addition, he makes $13,153,600 as President, Chief Executive Officer и Director at Bluebird bio Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Leschly BLUE stock SEC Form 4 insiders trading

Nick has made over 48 trades of the Bluebird bio Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 4,290 units of BLUE stock worth $33,462 on 11 January 2023.

The largest trade he's ever made was exercising 203,355 units of Bluebird bio Inc stock on 4 March 2021 worth over $1,118,453. On average, Nick trades about 15,940 units every 46 days since 2013. As of 11 January 2023 he still owns at least 280,149 units of Bluebird bio Inc stock.

You can see the complete history of Mr. Leschly stock trades at the bottom of the page.

Nick Leschly biography

Nick Leschly serves as President, Chief Executive Officer, Director of the Company. Mr. Leschly is a Class I director who has served as our President and Chief Executive Officer since September 2010. Previously, he served as our Interim Chief Executive Officer from March 2010 to September 2010. Formerly a partner of Third Rock Ventures, L.P. since its founding in 2007, Mr. Leschly played an integral role in the overall formation, development and business strategy of several of Third Rock’s portfolio companies, including Agios Pharmaceuticals, Inc. and Edimer Pharmaceuticals, Inc. Prior to joining Third Rock, he worked at Millennium Pharmaceuticals, Inc. (now a subsidiary of Takeda), leading several early-stage drug development programs and served as the product and alliance leader for VELCADE. Mr. Leschly also founded and served as Chief Executive Officer of MedXtend Corporation. Mr. Leschly currently serves on the Board of Directors of Synlogic, Inc. (NASDAQ: SYBX) and formerly served on the Board of Directors of Proclara Biosciences, Inc. He received his B.S. in molecular biology from Princeton University and his M.B.A. from The Wharton School of the University of Pennsylvania.

What is the salary of Nick Leschly?

As the President, Chief Executive Officer и Director of Bluebird bio Inc, the total compensation of Nick Leschly at Bluebird bio Inc is $13,153,600. There are no executives at Bluebird bio Inc getting paid more.

How old is Nick Leschly?

Nick Leschly is 47, he's been the President, Chief Executive Officer и Director of Bluebird bio Inc since 2010. There are 18 older and 3 younger executives at Bluebird bio Inc. The oldest executive at Bluebird bio Inc is Wendy Dixon, 64, who is the Independent Director.

What's Nick Leschly's mailing address?

Nick's mailing address filed with the SEC is C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE, MA, 02142.

Insiders trading at Bluebird bio Inc

Over the last 11 years, insiders at Bluebird bio Inc have traded over $130,743,125 worth of Bluebird bio Inc stock and bought 6,469 units worth $399,874 . The most active insiders traders include Steven Gillis, John Maraganore и Robert I Tepper. On average, Bluebird bio Inc executives and independent directors trade stock every 8 days with the average trade being worth of $6,033. The most recent stock trade was executed by Thomas J Klima on 3 June 2024, trading 3,834 units of BLUE stock currently worth $3,719.

What does Bluebird bio Inc do?

we are leading the gene therapy revolution. our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing – providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. we have a lot of energy, and it’s not just the abundance of coffee that keeps us going. find out what sparks our excitement and inspires us every day.

Complete history of Mr. Leschly stock trades at Bluebird bio Inc и Synlogic Inc

Bluebird bio Inc executives and stock owners

Bluebird bio Inc executives and other stock owners filed with the SEC include:

• Nick Leschly,
  President, Chief Executive Officer, Director
• William Baird,
  Chief Financial Officer
• David Davidson,
  Chief Medical Officer
• Philip Gregory,
  Chief Scientific Officer
• Jason Cole,
  Chief Operating Officer and Legal Officer, Secretary
• Nick Leschly,
  Pres & Director
• William Sellers,
  Independent Director
• William D. Baird III,
  Principal Financial & Accounting Officer
• Daniel Lynch,
  Independent Chairman of the Board
• Jason F. Cole Esq.,
  Chief Strategy & Financial Officer
• Thomas J. Klima,
  Chief Commercial Officer & COO
• Mark Vachon,
  Independent Director
• David Schenkein,
  Independent Director
• Wendy Dixon,
  Independent Director
• John Agwunobi,
  Independent Director
• Ingrid Goldberg,
  VP, Investor Relations
• Denice Torres,
  Director
• Joanne Smith-Farrell,
  Chief Business Officer
• Alison Finger,
  Chief Commercial Officer
• Katy Burnett,
  Interim Principal Accounting Officer
• Richard Colvin M.D., Ph.D.,
  Chief Medical Officer
• Andrea Walton,
  Chief People Officer
• Katherine Edna Breedis C.F.A., CMT,
  Interim CFO, Principal Financial Officer & Principal Accounting Officer
• Anne-Virginie Eggimann M.Sc.,
  Chief Regulatory Officer
• Melissa Bonner,
  Sr. VP of Research
• Dr. Liviu Niculescu M.D., Ph.D.,
  Sr. VP of Global Medical Affairs
• Sarah Alspach,
  Chief Communications Officer
• Kathleen A. Wilkinson,
  Chief People Officer
• Elizabeth Pingpank,
  Director of Corp. Communications
• Helen C. Fu,
  Sr. VP, Gen. Counsel & Sec.
• Jessica Whitten,
  VP, Global Controller & Chief Accounting Officer
• Kasra Kasraian,
  Sr. VP of Technical Devel. & Operations
• Gina R. Consylman CPA,
  Chief Financial Officer
• Andrew Obenshain,
  Pres, CEO & Director
• John Maraganore,
  Director
• James Mandell,
  Director
• Susanna Gatti High,
  Chief Operating Officer
• Eric Sullivan,
  Principal Accounting Officer
• Andrew Obenshain,
  President and CEO
• Douglas Melton,
  
• Mary Lynne Hedley,
  Director
• Kory James Wentworth,
  Principal Accounting Officer
• Thomas J Klima,
  See Remarks
• Charlotte Jones Burton,
  
• Axel Polack,
  Director
• Geert Jan Mulder,
  Director
• Christopher Krawtschuk,
  Chief Financial Officer
• Mitchell H. Finer,
  Chief Scientific Officer
• James M. Detore,
  Chief Financial Officer
• Venture Fund Vii Lparch Ven...,
  
• Robert I Tepper,
  Director
• Rock Ventures Lptrv Gp, Llc...,
  
• Linda Bain,
  VP, Fin. & Business Operations
• Rock Ventures Lp Third Rock...,
  
• Jeffrey T. Walsh,
  Chief Strategy Officer
• Steven Gillis,
  Director
• Richard A. Paulson,
  
• Gina Consylman,
  Chief Financial Officer
• Anne Virginie Eggimann,
  Chief Regulatory Officer
• Jessica Whitten,
  Chief Accounting Officer
• Marcela V. Maus,
  Director
• Sarah Js Glickman,
  Director
• Ramy Ibrahim,
  Director
• Joseph Vittiglio,
  Chief Business & Legal Officer
• Richard A Colvin,
  Chief Medical Officer
• Najoh Tita Reid,
  
• Elisabeth Leiderman,
  
• Michael Cloonan,
  
• O. James Sterling,
  Chief Financial Officer